000303211 001__ 303211
000303211 005__ 20250829113350.0
000303211 0247_ $$2doi$$a10.1016/j.jprot.2025.105507
000303211 0247_ $$2pmid$$apmid:40716489
000303211 0247_ $$2ISSN$$a1874-3919
000303211 0247_ $$2ISSN$$a1876-7737
000303211 0247_ $$2altmetric$$aaltmetric:179658120
000303211 037__ $$aDKFZ-2025-01562
000303211 041__ $$aEnglish
000303211 082__ $$a540
000303211 1001_ $$aTeibo, John Oluwafemi$$b0
000303211 245__ $$aProteomics analysis reveals early event molecular effectors of anti-CD19 CAR-T cell therapy in hematological cancer.
000303211 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2025
000303211 3367_ $$2DRIVER$$aarticle
000303211 3367_ $$2DataCite$$aOutput Types/Journal article
000303211 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756459989_12785
000303211 3367_ $$2BibTeX$$aARTICLE
000303211 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303211 3367_ $$00$$2EndNote$$aJournal Article
000303211 500__ $$aVolume 321, 30 October 2025, 105507Journal of Proteomics
000303211 520__ $$aChimeric antigen receptor T-cell (CAR-T) therapy is at the forefront of the field of cell immunotherapy. In this study, we generated an anti-CD19 CAR-Jurkat T cell line using a locally produced second-generation anti-CD19 CAR construct, which allowed us to analyse early proteomic changes that are crucial for comprehending the signalling pathways and mechanism of action of this CAR-T cell. SILAC-heavy tagged RAJI B-cells and anti-CD19 CAR-Jurkat T-cells were co-cultured for ten minutes. The proteomic profiles were acquired via DIA methodology on the Orbitrap Astral LC-MS/MS platform. The proteome was extensively covered, resulting in about 8800 protein identifications at 1 % FDR. The effector CAR-Jurkat cells showed proteomic changes involving antigen presentation by CD74. The target RAJI B-cells exhibited more significant alterations. Effector proteins, namely CD247, CD28, DAP, LCK, p38 MAPK, and CASP3, were validated, as they have critical roles in antigen presentation, T-cell activation, and apoptosis. Pharmacological inhibition of LCK using Dasatinib further suggested its pivotal role in early CAR-T signalling. This study led us to identify proteins that function as molecular effectors of anti-CD19 CAR-T cell therapy during the initial phases of CAR-T-target cell engagement, advancing our knowledge of the mechanism and signalling pathways that will support CAR-T cell development. SIGNIFICANCE: Chimeric antigen receptor T-cell (CAR-T cell) therapy is state-of-the-art in cell and immunotherapy. Determining important players in cellular communication and signalling mediated by membranes and intracellular proteins require understanding the connection between tumours and modified cells. We employed global proteomics in this study to better grasp the functional protein networks using a high-sensitivity mass spectrometric platform for protein identification and quantification. We identified proteins as molecular effectors of anti-CD19 CAR-T cell treatment during the early stages of CAR-T-target cell interaction. Our understanding of the mechanism and signalling pathways will promote the development of new CAR constructs and improve the efficacy and ability to overcome the resistance of this innovative cancer treatment strategy, which will advance the identification of adjuvant molecules for the regulation of CAR-T responses.
000303211 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000303211 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303211 650_7 $$2Other$$aCAR-T cell
000303211 650_7 $$2Other$$aEarly Signalling event
000303211 650_7 $$2Other$$aHematological Cancer
000303211 650_7 $$2Other$$aMolecular effectors
000303211 650_7 $$2Other$$aProteomics
000303211 650_7 $$2Other$$aSILAC
000303211 7001_ $$aSilveira, Roberta Maraninchi$$b1
000303211 7001_ $$aSilvestrini, Virginia Campos$$b2
000303211 7001_ $$aArchiolli, Izadora$$b3
000303211 7001_ $$aPaulaMasson, Ana$$b4
000303211 7001_ $$ade Morais, Beatriz Pereira$$b5
000303211 7001_ $$aSchmidt, Dayane$$b6
000303211 7001_ $$aDos Santos, Matheus Henrique$$b7
000303211 7001_ $$aFerreira, Germano Aguiar$$b8
000303211 7001_ $$aThomé, Carolina Hassibe$$b9
000303211 7001_ $$0P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1$$aHelm, Dominic$$b10$$udkfz
000303211 7001_ $$aNirujogi, Raja Sekhar$$b11
000303211 7001_ $$aAlessi, Dairo Renato$$b12
000303211 7001_ $$aPicanço-Castro, Virginia$$b13
000303211 7001_ $$ade Souza, Lucas Eduardo Botelho$$b14
000303211 7001_ $$aFaça, Vitor Marcel$$b15
000303211 773__ $$0PERI:(DE-600)2400835-7$$a10.1016/j.jprot.2025.105507$$gp. 105507 -$$p105507$$tJournal of proteomics$$v321$$x1874-3919$$y2025
000303211 909CO $$ooai:inrepo02.dkfz.de:303211$$pVDB
000303211 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)daaed5a5b968028e6e95d273150d5ab1$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000303211 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000303211 9141_ $$y2025
000303211 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ PROTEOMICS : 2022$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-10
000303211 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-10
000303211 9201_ $$0I:(DE-He78)W120-20160331$$kW120$$lProteomics$$x0
000303211 980__ $$ajournal
000303211 980__ $$aVDB
000303211 980__ $$aI:(DE-He78)W120-20160331
000303211 980__ $$aUNRESTRICTED